Please login to the form below

Not currently logged in
Email:
Password:

liver damage

This page shows the latest liver damage news and features for those working in and with pharma, biotech and healthcare.

Blood disorder specialists Imara raises $63m

Blood disorder specialists Imara raises $63m

chest syndrome and damage to other organs including the liver, spleen, kidney and the brain.

Latest news

  • Intercept NASH drug closes in on FDA approval Intercept NASH drug closes in on FDA approval

    2017 was the subject of an FDA warning over liver damage. ... Intercept’s trial enrolled mainly patients with stage 2 and 3 liver fibrosis, with a small group of patient with mild (stage) symptoms.

  • Roche enters NASH race with deal to buy Jecure Roche enters NASH race with deal to buy Jecure

    It is characterised by a build-up of fat that can lead to liver fibrosis, cirrhosis and - in some patients - the need for a liver transplant. ... Inflammation is considered to be a trigger for the liver damage that characterises the disease.

  • FDA rejects Allergan’s uterine fibroid drug over safety concerns FDA rejects Allergan’s uterine fibroid drug over safety concerns

    Its investigational drug has been linked to 'serious' liver damage issues in Europe. ... It has been on the European market since 2012, but earlier this year the European Medicines Agency (EMA) implemented several safety measurements after reports of

  • Alexion adds to pipeline rebuild with $855m Wilson buy Alexion adds to pipeline rebuild with $855m Wilson buy

    in turn - severe liver damage as well as neurological symptoms such as impaired movement, speech, swallowing, and psychiatric disorders. ... WTX101 is an orally-active copper binder that can address the build-up in blood and the liver, and has a novel

  • Biogen and AbbVie pull MS drug Zinbryta from the market Biogen and AbbVie pull MS drug Zinbryta from the market

    Escalating concerns about the safety of Zinbryta (daclizumab) - and particularly cases of liver damage and immune-related conditions - are behind the decision, which was announced on the same day that the ... Zinbryta was approved for marketing in 2016

More from news
Approximately 1 fully matching, plus 51 partially matching documents found.

Latest Intelligence

  • ‘How is your day?’ ‘How is your day?’

    swelling that obstructs airways) and Alpha-1 Antitrypsin Deficiency (causes chronic emphysema and liver damage).

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
HAVAS Just::

HAVAS Just:: is a different kind of healthcare communications agency. Our mission is to create campaigns that make people think....

Latest intelligence

Empowered patients: shaking the foundations of healthcare
Precision medicine represents a new paradigm in healthcare.This new approach to treating and preventing disease views the patient holistically, analysing their genes, environment and lifestyle, and using this information to...
A uniquely English genomic medicine service
The UK National Health Service is developing one standardised approach to embedding precision medicine across the whole of England. Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist...
Blended Intelligence
Data is the most valued commodity of the modern world. For P&P it's all about the application....

Infographics